Consensus Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Real-time Estimate Cboe BZX Other stock markets 16:08:46 10/09/2024 BST			5-day change	1st Jan Change
16.17 ^USD	-0.86%		-2.66%	-15.55%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

Evolution of the Average Target: Arcus Biosciences, Inc.

Evolution of the Target Price: Arcus Biosciences, Inc.

Changes in Analyst Recommendations: Arcus Biosciences, Inc.

7403b4d7a6a.arNozzXCxwDUED184Ae0WFze45Ld4DlD4VHHoGDZaCY.J-segwSdqmG_RW8bp17TbzmridO5hUl7t2iWx1OKOBA9_wm4Aa_yRrgkCQ~5635ca61d07fbf40b24c5991cf70dcef

Analysts' recommendations: Arcus Biosciences, Inc.

Truist Lowers Price Target on Arcus Biosciences to $44 From $50, Maintains Buy Rating	06-24	MT
Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating	06-03	MT
Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating	01-30	MT
Wedbush Lowers Arcus Biosciences' PT to $30 From $36 After Announced Plans to Discontinue Enrollment for Phase 3 ARC-10 Study; Keeps Outperform Rating	01-30	MT
Morgan Stanley Cuts Price Target on Arcus Biosciences to $35 From $38, Maintains Overweight Rating	11-13	MT
Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating	11-08	MT
Citigroup Adjusts Price Target on Arcus Biosciences to $44 From $41, Maintains Buy Rating	24/08/23	MT
Morgan Stanley Trims Price Target on Arcus Biosciences to $38 From $40, Maintains Overweight Rating	08/08/23	MT
Cantor Fitzgerald Reiterates Arcus Biosciences' Overweight Rating, $46 Price Target	12/07/23	MT
Citigroup Adjusts Arcus Biosciences Price Target to $41 From $40, Maintains Buy Rating	26/05/23	MT
Barclays Adjusts Price Target on Arcus Biosciences to $35 From $60, Maintains Overweight Rating	21/12/22	MT
Citigroup Adjusts Arcus Biosciences' Price Target to $42 From $37, Keeps Buy Rating	20/12/22	MT
Citigroup Lowers Price Target on Arcus Biosciences to $37 From $40, Maintains Buy Rating	23/11/22	MT
BofA Securities Starts Arcus Biosciences at Neutral With $33 Price Target	18/11/22	MT
SVB Securities Adjusts Price Target on Arcus Biosciences to $38 From $40, Maintains Outperform Rating	03/11/22	MT
Berenberg Bank Adjusts Arcus Biosciences Price Target to $60 From $68, Maintains Buy Rating	03/11/22	MT
Morgan Stanley Starts Arcus Biosciences at Overweight With $40 Price Target	11/10/22	MT
Goldman Sachs Adjusts Arcus Biosciences' Price Target to $29 From $28, Maintains Neutral Rating	04/08/22	MT
SVB Securities Adjusts Arcus Biosciences' Price Target to $49 from $66, Keeps Outperform Rating	04/08/22	MT
Wedbush Adjusts Price Target on Arcus Biosciences to $36 From $42, Keeps Outperform Rating	04/08/22	MT
Truist Securities Adjusts Arcus Biosciences' Price Target to $50 from $77, Keeps Buy Rating	08/07/22	MT
Goldman Sachs Adjusts Arcus Biosciences Price Target to $28 From $48, Maintains Neutral Rating	12/05/22	MT
Wedbush Lowers Arcus Biosciences' Price Target to $42 from $67, Notes Increased Risk for TIGIT Program; Keeps Outperform Rating	11/05/22	MT
Goldman Sachs Adjusts Arcus Biosciences' Price Target to $43 From $45; Neutral Rating Kept	14/01/22	MT
Berenberg Bank Adjusts Arcus Biosciences' Price Target to $68 From $60, Maintains Buy Rating	19/11/21	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	ARCUS BIOSCIENCES, INC.					+103.10%
	LONZA GROUP AG					+14.81%
	IQVIA HOLDINGS INC.					+14.81%
	ALNYLAM PHARMACEUTICALS, INC.					+11.85%
	CELLTRION, INC.					+28.46%
	MODERNA, INC.					+64.10%
	ICON PUBLIC LIMITED COMPANY					+22.33%
	UNITED THERAPEUTICS CORPORATION					+0.57%
	BIO-TECHNE CORPORATION					+14.52%
	MEDPACE HOLDINGS, INC.					+19.90%
	Average					+29.44%
	Weighted average by Cap.					+22.58%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.31USD

Average target price

33.12USD

Spread / Average Target

+103.10%

High Price Target

46.00USD

Spread / Highest target

+182.04%

Low Price Target

23.00USD

Spread / Lowest Target

+41.02%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Citigroup
Mizuho Securities
Wedbush
Morgan Stanley
Cantor Fitzgerald
Barclays
BofA Securities
Berenberg Bank
SVB Securities LLC
Goldman Sachs
Truist Securities
SVB Leerink